Navigation Links
NeurogesX Reports First Quarter 2009 Results
Date:5/7/2009

ation (FDA) in October 2008 for PHN, which was accepted and filed by the FDA in December 2008. On March 19, 2009, a marketing authorization application (MAA) for Qutenza received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending approval for the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain. The Company is currently awaiting the European Commission's decision on the CHMP's opinion, a process which normally takes approximately 60 to 90 days.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently evaluating the timing of entering Phase 2 development.

NeurogesX' early stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected timing and outcome of regulatory decisions and the label approval being sought or that may be obtained with respect to the MAA for Qutenza in the European Union and the NDA for Qutenza with the FDA, including the timing of European Commission decision on the MAA and the PDUFA date for
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
2. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
3. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
4. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
5. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
6. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. NeurogesX Reports Third Quarter 2008 Results
8. NeurogesX to Report Third Quarter 2008 Financial Results
9. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
10. NeurogesX Responds to EMEAs Day 120 Questions
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 The ... results from a survey of European physicians at ... on Innovation and Biological Therapies" at the Spanish ... event, hosted by EuropaBio and the Spanish Bioindustry ... of Health, physicians from Spanish oncology and rheumatology ...
(Date:11/26/2014)... Charlotte, NC (PRWEB) November 25, 2014 ... High Intensity Focused Ultrasound (HIFU) devices, recently participated ... “ Small Renal Mass 360° .” Key opinion ... and therapeutic advances related to small renal masses ... learn about different ablative technologies in hands-on labs. ...
(Date:11/26/2014)... Miles Holder, formerly of Micron Research ... Products team as Sales/Marketing Manager. Mr. Holder has over ... for the graphite industry. , “We are thrilled to ... Dave Trinkley, VP of Market and Product Development for ... in the graphite industry, along with his proven track ...
(Date:11/26/2014)... 25, 2014 Bio-Techne Corporation (NASDAQ: ... Robert Gavin to serve in a newly created ... Division.  Mr. Gavin will be responsible for managing the ... the ProteinSimple business acquired in July 2014 and the ... Jose, California -based ProteinSimple develops and commercializes proprietary ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... , , SADDLE RIVER, N.J., July ... provider of sales and marketing support to U.S. pharmaceutical companies, ... results on Wednesday, August 5, 2009 after the market close. ... conference call beginning at 4:30 p.m. Eastern time on August 5, ...
... , , BRISBANE, Calif., July 29 ... it will release second quarter 2009 financial results on Thursday, August ... call and webcast will be hosted by InterMune at 4:30 p.m. ... access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ...
... , , , ... (Nasdaq: OSTE ), a leader in the emerging ... in a July 24, 2009 letter to the Company, the ... establishing restrictions on the importation and distribution of tissue products ...
Cached Biology Technology:PDI, Inc. to Hold Second Quarter 2009 Financial Results Conference Call on Wednesday, August 5, 2009 2InterMune to Release Second Quarter Financial Results on August 6 2Osteotech Resumes Shipments of Bulgarian Tissue 2Osteotech Resumes Shipments of Bulgarian Tissue 3
(Date:11/7/2014)... Dr. Debra Auguste, associate professor, biomedical engineering, in ... College of New York, have identified a molecule ... of the most aggressive forms of breast cancer. ... high mortality rate owing to aggressive proliferation and ... However, Professor Auguste,s team, discovered the overexpression of ...
(Date:11/6/2014)... A groundbreaking paper from a team of Florida State ... how plants could adapt to and survive environmental swings ... in the latest issue of the journal The ... complex of DNA and proteins) is organized in a ... some genes are turned on and others are turned ...
(Date:11/6/2014)... 6, 2014 - Insilico Medicine, Inc, a Baltimore-based ... age related diseases announced a research collaboration with ... Champions Oncology, Inc (OTC: CSBR). , "There are ... medicine, but Champions Oncology,s TumorGraft technology is unique ... chemotherapy regimen experimentally generating vast amounts of valuable ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... important for the survival of many types of cells ... cells that connect the cerebral cortex with the spinal ... amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). ... investigators from Massachusetts General Hospital (MGH) and the Harvard ...
... during the earliest phases of infection appears to depend ... called HLA Class I that have been inherited, as ... molecules display to the T lymphocytes that usually destroy ... issue of PLOS Medicine, researchers from the Partners AIDS ...
... packages for scientists eager to find natural substances to ... that is smaller than the proverbial gnat's eyelash. , ... technology, or NMR, scientists have unlocked secrets hidden in ... common two-stripe walking sticks, which are relatively harmless, plant-eating ...
Cached Biology News:Growth factor stimulates rapid extension of key motor neurons in brain 2Early-stage immune system control of HIV may depend on inherited factors 2Early-stage immune system control of HIV may depend on inherited factors 3One-of-a-kind imaging probe reveals secrets useful for drug discovery 2One-of-a-kind imaging probe reveals secrets useful for drug discovery 3
Automated centrifuge for the processing of microplates and tubes; can be integrated into automated process using inexpensive robotics due to its unique sample handling platform....
OptiBuffer is a fully optimised medium, designed for,the electroporation of eukaryotic cells. OptiBuffer,improves both transfection efficiencies and survival,rates over PBS or other standard culture...
...
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
Biology Products: